Shanghai Institute of Pharmaceutical Industry

Zhejiang Hisun Pharmaceutical Co., Ltd.

China State Institute of Pharmaceutical Industry

Scinopharm Singapore Pte Ltd.

Meihua Xie

Fuli Zhang

Taizhi Wu

Hua Bai

Rusheng Bao

Meng Hu

Daoxin Chen

Rentong Sun

Jialiang Zhong

Anping Lai

The present invention discloses a salt derivative of 1-(3-methanesulfonamidobenzyl)-6-methoxy-7-benzyloxy-1,2,3,4-tetrahydroisoquinoline. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL.

Salt derivative of tetrahydroisoquinoline and crystalline thereof and preparation method therefore and application thereof

The present invention discloses a process for obtaining 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate by the reaction of 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole, or its hydrolysis product, or its ring-opening product, with alcohol under appropriate catalytic conditions. Furthermore, the present invention also provides a process for obtaining high purity 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole.

Process for the preparation of 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylates

The present invention provides N-methylethylcarbamino-3-[(S)-1-(methyl-[(S)-1-phenylethyl]amino)ethyl]phenyl ester represented by formula (II) and its preparation method. The present invention also provides (S)-1-(3-methoxyphenyl)-N-methyl-N&#x2014;[(S)-1-phenylethyl]ethylamine and 3-[(S)-1-(methyl-[(S)-1-phenylethyl]amino)ethyl]phenol as intermediates of the compound represented by formula (II), and the use of the compound represented by formula (II) for preparing rivastigmine used for treating Alzheimer disease.

Preparation method of rivastigmine, its intermediates and preparation method of the intermediates

Growing community of inventors

Shanghai, China

Meihua Xie